Rosiglitazone
|
Better Known as: Avandia
- Marketed By: GlaxoSmithKline (No Longer Marketed)
- Major Indication: Hypoglycemia & Type 2 Diabetes
- Drug Class: PPAR-γ Activator - Thiazolidinedione (Glitazones)
- Date of FDA Approval (Patent Expiration): 1999 (2012)
- 2009 (2006) Sales: $400 Million ($2.5 Billion)[1]
- Why You Should Care: Once the best selling Diabetes treatment in the world. Lawsuits and legal action being pursued against GlaxoSmithKline for manipulation of clinical data upon which Avandia was approved with regards to its side effect profile.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| Glitazone Comparison | |||||
|---|---|---|---|---|---|
| Parameter | Pioglitazone (Actos) | Rosiglitazone (Avandia) | |||
| Tmax (hr) | |||||
| Cmax (ng/ml) | |||||
| Bioavailability (%) | |||||
| Protein Binding (%) | 99 | 99 | |||
| T1/2 (hr) | 3-7 | 3-4 | |||
| AUC (ng/ml/hr) | |||||
| IC50 (nM) | |||||
| Equivalent Dosage (mg) | |||||
| Metabolism | Hepatic (CYP2C8) |
Hepatic (CYP2C8) | |||
Effectiveness and Side Effects
Effectiveness
Side Effects
Interesting Facts
The Jist
References